Fig. 7

Potential drugs targeting lipid metabolism for patients with TNBC, predicted by pRRophetic. IC50 of BMS-754807 (A), OSI.906 (B), and VX.680 (C) in the TNBC clinical subgroup; Chemical structure of BMS-754807 (D), OSI.906 (E), and VX.680 (F). TNBC, triple-negative breast cancer.